Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Association of On-Treatment Neutrophil-to-Eosinophil Ratio With Treatment Responses in Patients With mRCC Treated With Nivolumab/Ipilimumab
  2. Impact of BMI on ICI Treatment Outcomes of Advanced RCC and UC in an Asian Population
  3. Cancer-Specific Mortality in Patients With T1a RCC Treated With Local Tumor Destruction vs Partial Nephrectomy
  4. Association of Weight Loss With Cabozantinib Use in Patients With mRCC
  5. Validity of Routine cfDNA Panel Testing in Patients With ccRCC
  6. Efficacy of Cabozantinib as Second-Line Therapy Based on Type of First-Line Therapy Received
  7. Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitor Therapy for mRCC
  8. Molecular Profiling of the Tumor Microenvironment in Renal Medullary Carcinoma
  9. HRQoL in Patients With Advanced RCC Treated With Pembrolizumab Plus Axitinib vs Sunitinib Monotherapy
  10. Nivolumab vs Cabozantinib in Second- or Third-Line Treatment of mRCC

Elsewhere

Recently Updated